Clinical Trials Logo

Filter by:
NCT ID: NCT01423500 Active, not recruiting - Clinical trials for Lymphoblastic Leukemia, Acute, Childhood;

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

ALL-SCT-BFMi
Start date: January 2007
Phase: Phase 3
Study type: Interventional

With this protocol the ALL-SCT BFM international study group wants - to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). - to evaluate the efficacy of hematopoietic stem cell transplantation (HSCT)from mismatched family or unrelated donors (MMD) as compared to HSCT from matched sibling donors or matched donors. - to determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. - to prospectively evaluate and compare the incidence of acute and chronic Graft-versus-Host-Disease (GvHD) after HSCT from matched sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).

NCT ID: NCT01419197 Active, not recruiting - Breast Cancer Clinical Trials

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

TH3RESA
Start date: February 2011
Phase: Phase 3
Study type: Interventional

This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in patients with metastatic or unresectable locally advanced/recurrent HER2-positive breast cancer. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg intravenously every 21 days or treatment of the physician's choice. Patients continue to receive study treatment until disease progression or unacceptable toxicity occurs. This study is also known under Roche study protocol number BO25734.

NCT ID: NCT01410045 Active, not recruiting - Turner Syndrome Clinical Trials

Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome

CRYO-X0
Start date: January 2011
Phase: N/A
Study type: Interventional

Ovarian insufficiency is common in Turner syndrome related to premature and rapid follicular apoptosis and spontaneous pregnancies are rare in this population. Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency. This study aims to assess the relevance of ovarian tissue cryopreservation in girls with Turner syndrome. Based on ovarian follicular density as primary outcome and karyotypic, clinical and hormonal markers as secondary outcomes, analysis of the study will allow to select the patients to whom the procedure would benefit the most.

NCT ID: NCT01402154 Active, not recruiting - Clinical trials for Adenocarcinoma of the Prostate

EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients

Start date: January 3, 2012
Phase:
Study type: Observational

The primary objective of this study is to evaluate the predictive value (in terms of remission) of a new technique for detecting circulating, functional, prostate cells among patients with localized adenocarcinoma of the prostate, and prior to any treatment.

NCT ID: NCT01401166 Active, not recruiting - Breast Cancer Clinical Trials

Patients' Preference of Herceptin (Trastuzumab) Subcutaneous Versus Intravenous Administration in HER2-positive Early Breast Cancer

Start date: October 2011
Phase: Phase 2
Study type: Interventional

This randomized, open-label, crossover study evaluated participants' preference and healthcare professional satisfaction with trastuzumab (Herceptin) subcutaneous (sc) versus intravenous (iv) administration in participants with HER2-positive early breast cancer.

NCT ID: NCT01400464 Active, not recruiting - Clinical trials for Giant Cell Arteritis

Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis

PREDICORT
Start date: July 2009
Phase: Phase 4
Study type: Interventional

The factors underlying the large interindividual variability in response to glucocorticoids in Giant Cell Arteritis are poorly understood. The investigators hypothesize that a part of this variability is related to pharmacokinetic factors determined by genetic polymorphism: hepatic clearance involving cytochromes P450 of the subfamily 3A (CYP3A) and drug efflux leukocyte conditioned by P-glycoprotein involved in multidrug resistance drugs (ABCB1). The investigators have designed a multicentric prospective pharmacokinetical and pharmacogenetic cohort study to assess the link between prednisolone clearance and the relapse risk in giant cell arteritis.

NCT ID: NCT01385176 Active, not recruiting - Heart Failure Clinical Trials

Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)

NECTAR-HF
Start date: September 21, 2011
Phase: N/A
Study type: Interventional

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

NCT ID: NCT01383512 Active, not recruiting - Subacute Stroke Clinical Trials

Rehabilitation Robotics After a Stroke

REM_AVC
Start date: June 2011
Phase: N/A
Study type: Interventional

Upper limb motor control after a stroke may be improved with rehabilitation robotics at a subacute stage. The aim of this multicenter controled randomized single blind study is to define the place of rehabilitation robotics at this phase of the rehabilitation process. Both groups will realize the same time of rehabilitation. The cost benefit ratio will be compared in each group through medical assessment of improvement and definition of the costs due to the rehabilitation process.

NCT ID: NCT01376752 Active, not recruiting - Clinical trials for Ovarian Epithelial Cancer Recurrent

Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

CHIPOR
Start date: April 26, 2011
Phase: Phase 3
Study type: Interventional

CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial ovarian cancer is able to improve the median Overall Survival (OS) by 12 months. In that hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10% failure, an overall number of 444 patients is required.

NCT ID: NCT01367106 Active, not recruiting - Clinical trials for 21-hydroxylase; Defect

Effects of "in UTERO" Exposure to Glucocorticoids

GLUCODEX
Start date: November 2012
Phase: N/A
Study type: Interventional

The main objective of this study is to show that the fetal exposure to excess of glucocorticoids is associated with a deficiency of the function beta insulin in the offspring adult.